Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tyrosine Kinase Inhibitors in Patients with AML

Stem Cell Investig; 2017 Jun 2; Chen, Pan, et al

Novel therapeutic drugs targeting key molecular defects in acute myeloid leukemia (AML) are being developed, with FMS-like tyrosine kinase 3 (FLT3) representing 1 of the most attractive targets, according to a recent review.

FLT3 mutants resulting from either internal tandem duplication or point mutations possess enhanced kinase activity and cause constitutive activation of signaling. To date, several small molecule inhibitors of FLT3 have been developed. The review focuses on the pathological role of mutant FLT3 in the development of AML, the current status of FLT3 inhibitor development, and mechanisms that cause resistance.

Citation:

Chen Y, Pan Y, Guo Y, et al. Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia. Stem Cell Investig. 2017;4:48. doi:10.21037/sci.2017.05.04.